Prevalence of depressive symptoms in a memory clinic cohort: a retrospective study
| Autor: | Flavia Loreto, Anna Fitzgerald, Mara Golemme, Stephen Gunning, Zarni Win, Neva Patel, Christopher Carswell, Richard Perry, Angus Kennedy, Paul Edison, Paresh Malhotra |
|---|---|
| Přispěvatelé: | Alzheimer's Society |
| Rok vydání: | 2022 |
| Předmět: |
1702 Cognitive Sciences
amyloid-β diagnostic uncertainty Alzheimer Disease mental disorders Prevalence Humans Cognitive Dysfunction Retrospective Studies Amyloid beta-Peptides Neurology & Neurosurgery Depression General Neuroscience amyloid-PET Neurodegenerative Diseases 1103 Clinical Sciences General Medicine clinical cohort Psychiatry and Mental health Clinical Psychology Positron-Emission Tomography Geriatrics and Gerontology 1109 Neurosciences Alzheimer’s disease Biomarkers dementia |
| Popis: | Background: Depression has been suggested to be a cause of reversible cognitive impairment but also a risk factor for neurodegenerative disease. Studies suggest that depression prevalence may be high in early onset dementia, particularly Alzheimer’s disease, but this has not been systematically assessed in a biomarker-validated clinical dementia cohort to date. Objective: To examine the prevalence, features, and association with amyloid pathology of lifetime depressive symptoms in a memory clinic cohort meeting appropriate use criteria for amyloid PET imaging. Methods: We included 300 patients from a single-center memory clinic cohort that received diagnostic biomarker evaluation with amyloid PET imaging according to appropriate use criteria. History of lifetime depressive symptoms was retrospectively assessed through structured review of clinical correspondence. Results: One hundred forty-two (47%) patients had a history of significant depressive symptoms (‘D+’). Of these, 89% had ongoing symptoms and 60% were on antidepressants at the time of presentation to our Clinic. Depressive symptoms were equally highly prevalent in the amyloid-positive and the heterogeneous group of amyloid-negative patients. Conclusion: Approximately half of patients who meet appropriate use criteria for amyloid PET have a history of depressive symptoms. We suggest that depression is an important feature of both neurodegenerative and non-neurodegenerative cognitive impairment and may contribute to the diagnostic uncertainty behind referral to amyloid PET. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|